Credits Available: 4.75 AMA PRA Category 1 Credit™ & 4.75 MOC points

Description: The goal of this initiative is to improve the care of patients with Duchenne muscular dystrophy (DMD). DMD is the most common childhood form of muscular dystrophy and characteristic manifestations are progressive muscle weakness, cardiorespiratory impairment, and premature death. Gene therapy provides a new avenue to treat life‐limiting neuromuscular disorders. Given the novelty of these therapies, clinicians involved in the care of patients with DMD may not be aware of their associated evidence and implementation. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with Duchenne muscular dystrophy.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Assistant
Target Specialties: Pediatrics, Neurology, Orthopedic Medicine/Sports Medicine, Physiatry/Rehabilitation

Suur Biliciler

UT Health Science Center at Houston, McGovern Medical School
Associate Professor of Neurology

I'm a neuromuscular specialist and a med-ed enthusiast My specific interests are inflammatory myopathies, muscular dystrophies, genetics of neuromuscular disorders, and nerve and muscle pathology. I advocate for a balanced approach, melding lifestyle medicine with cutting-edge treatments. Whether it's dissecting the pathology of the PNS or championing nutrition and exercise, I'm dedicated to enhancing patient well-being and advancing medical frontiers, one discovery at a time.